Ondine Biomedical Inc Common Share OBI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 7.50
- Day Range
- GBX 7.00–8.00
- 52-Week Range
- GBX 5.00–17.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 2.08 Bil
- Volume/Avg
- 145,500 / 479,479
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 29.29
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 43
- Website
- https://www.ondinebio.com
Valuation
|
Metric
|
OBI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.90 |
Price/Sales | 29.29 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OBI
|
|---|---|
Quick Ratio | 1.71 |
Current Ratio | 2.34 |
Interest Coverage | −464.17 |
Quick Ratio
OBI
Profitability
|
Metric
|
OBI
|
|---|---|
Return on Assets (Normalized) | −101.11% |
Return on Equity (Normalized) | −132.51% |
Return on Invested Capital (Normalized) | −127.20% |
Return on Assets
OBI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Vqjtvnzn | Ttqytj | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gkbbspjr | Lyxhty | $114.2 Bil | |||
| Moderna Inc
MRNA
| Yhzmbgll | Fpsyk | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Wwxwyqmh | Zmh | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Gcckcfc | Smgzv | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vtgwkykj | Mdhjp | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cxkmnfwy | Ghzlh | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Svgsmhmt | Lmdsj | $12.8 Bil | |||
| Incyte Corp
INCY
| Ddtcsgzf | Gjzxpl | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Sfrpmpspq | Fkzpwsw | $12.2 Bil |